相关实验视频
Updated: Jun 24, 2025
10:20
In vitro Measurements of Tracheal Constriction Using Mice
Published on: June 25, 2012
20.8K
重复剂量的卡波普利尔会通过调节大鼠的TRPV1受体来诱导气道过敏反应
Janiana Raíza Jentsch Matias de Oliveira1, Mayara Alves Amorim1, Vitor Hélio de Souza Oliveira1
1Department of Pharmacology, Federal University of Paraná, Brazil.
Pulmonary pharmacology & therapeutics
|June 1, 2024
概括
重复服用卡普托普里尔剂量可提高大鼠呼吸道中暂时受体潜在化物1 (TRPV1) 的调节,从而增加了呼吸道的高响应性. 向TRPV1可能会减轻卡波普里尔的作用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 呼吸系统医学 呼吸系统医学
- 神经科学是一个神经科学.
背景情况:
- 卡普托普里尔治疗可能会导致呼吸道不良影响.
- 暂时受体潜在化物1 (TRPV1) 在重复卡波普利尔剂量效应中的作用尚不清楚.
- 了解TRPV1的作用至关重要,因为卡波普利尔通常是连续使用的.
研究的目的:
- 为了研究TRPV1在卡波普里尔诱导的气道影响中的作用,在单次与重复剂量方案下.
- 为了比较不同频率的卡普托普里尔治疗对呼吸道功能和炎症的影响.
主要方法:
- 获得单剂或重复剂量的卡波普利尔的老鼠.
- 进行了气道阻力,支气管洗 (BAL) 和组织学分析.
- 免疫组织化学被用来评估TRPV1表达和神经元变化.
- 药理干预包括B2抗剂 (HOE140) 和TRPV1阳性神经元退化.
主要成果:
- 单剂量卡普托普里尔诱导了急性呼吸道对布拉迪基宁和素的过敏反应.
- 在单剂量大鼠中,TRPV1阳性神经元退化和B2对抗性降低了超反应性.
- 重复服用卡波普利尔剂量导致BAL中的白细胞暂时流入,并显著上调TRPV1表达.
- 由于TRPV1阳性神经元退化,TRPV1上调被减弱.
结论:
- 重复服用卡普托普里尔可以提高老鼠呼吸道中TRPV1的表达.
- 对TRPV1的敏感性有助于呼吸道的高反应性和炎症.
- 向TRPV1是一个潜在的治疗策略,可以减少卡波普里尔对呼吸道的不良影响.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
711
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
711
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
617
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
617
01:20Desensitization and Tachyphylaxis
1.7K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.7K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
153
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
153
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
167
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
167